49,XXXXY syndrome is a rare sex chromosome aneuploidy and characterized by mental retardation, skeletal defects, craniofacial anomalies and hypogonadism. The increased frequency of diabetes mellitus in patients with Klinefelter syndrome and other types of X-chromosome polysomy has been reported, but no cases of diabetes mellitus in adult with 49,XXXXY syndrome have been reported so far. We report an 18-year-old patient with 49,XXXXY syndrome accompanying diabetes mellitus.

1.
Kleczkowska A, Fryns JP, Van den Berghe H: X-chromosome polysomy in the male. The Leuven experience 1966–1987. Hum Genet 1988;80:16–22.
2.
Linden MG, Bender BG, Robinson A: Sex chromosome tetrasomy and pentasomy. Pediatrics 1995;96:672–682.
3.
Zaleski WA, Houston CS, Pozsonyi J, Ying KL: The XXXXY chromosome anomaly: report of three new cases and review of 30 cases from the literature. Can Med Assoc J 1966;94:1143–1154.
4.
Peet J, Weaver DD, Vance GH: 49,XXXXY: a distinct phenotype. Three new cases and review. J Med Genet 1998;35:420–424.
5.
Nielsen J, Johansen K, Yde H: Frequency of diabetes mellitus in patients with Klinefelter’s syndrome of different chromosome constitutions and the XYY syndrome. Plasma insulin and growth hormone level after a glucose load. J Clin Endocrinol Metab 1969;29:1062–1073.
6.
Takeuchi Y, Murata Y, Sintani J, Masukawa H, Nakamura R, Oi K, Kato Y, Niinomi M: Klinefelter’s syndrome accompanied by mixed connective tissue disease and diabetes mellitus. Intern Med 1999;38:875–881.
7.
Christensen MF, Therkelsen AJ: A case of the XXXXY chromosome anomaly with four maternal X chromosomes and diabetic glucose tolerance. Acta Paediatr Scand 1970;59:706–710.
8.
Lewis FJ, Froland A, Sanger R, Race RR: Source of the X chromosomes in two XXXXY males. Lancet 1964;14:589.
9.
Hassold T, Pettay D, May K, Robinson A: Analysis of non-disjunction in sex chromosome tetrasomy and pentasomy. Hum Genet 1990;85:648–650.
10.
Fraccaro M, Kaijser K, Lindsten J: A child with 49 chromosomes. Lancet 1960;ii:899–902.
11.
Barr ML, Carr DH, Pozsonyi J, Welson RA, Dunn HG, Jacobson TS, Miller JR, Lewis M, Chown B: The XXXXY sex chromosome abnormality. Can Med Assoc J 1962;87:891–901.
12.
Sheridan MK, Radlinski S: Brief report: a case study of an adolescent male with XXXXY Klinefelter’s syndrome. J Autism Dev Disord 1988;18:449–456.
13.
Sheridan MK, Radlinski SS, Kennedy MD: Developmental outcome in 49,XXXXY Klinefelter syndrome. Dev Med Child Neurol 1990;32:532–539.
14.
Dotsch J, Foerster W, Holl R, Rascher W, Kiess W: Case of XXXXY syndrome. Development throughout adolescence and endocrine aspects. Horm Res 2000;53:154–156.
15.
Defray R, Papoz L, Barny S, Bonnot-Lours S, Caces E, Simon D: Hormonal status and NIDDM in the European and Melanesian populations of New Caledonia: a case-control study. The CALedonia DIAbetes Mellitus (CALDIA) Study Group. Int J Obes Relat Metab Disord 1998;22:927–934.
16.
Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L: Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;143:889–897.
17.
Pei D, Sheu WH, Jeng CY, Liao WK, Fuh MM: Insulin resistance in patients with Klinefelter’s syndrome and idiopathic gonadotropin deficiency. J Formos Med Assoc 1998;97:534–540.
18.
Ota K, Suehiro T, Ikeda Y, Arii K, Kumon Y, Hashimoto K: Diabetes mellitus associated with Klinefelter’s syndrome: a case report and review in Japan. Intern Med 2002;41:842–847.
19.
Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E: Klinefelter’s syndrome. Lancet 2004;364:273–283.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.